Press Enter to search · ESC to close

US Stocks

Akeso Falls Over 24% After Ivonescimab’s First US Marketing Application Rejected

Akeso’s shares dropped more than 24% after the company’s first US marketing application for its oncology immunotherapy drug ivonescimab was not approved. The rejection marks a setback for the Chinese biotech’s lead immuno-oncology candidate in the US market.

Original source

AI take

The size of the share reaction reflects how much of Akeso's equity story had been tied to US market entry for its lead immuno-oncology asset, not just to domestic sales. A first marketing application rejection for a Chinese biotech's flagship candidate also lands in a sector where US regulatory clearance has become a key differentiator for valuation. Whether Akeso discloses the specific grounds for the rejection, and how quickly a refiling path becomes visible, is the open question.

Generated by AI for reference only.

Share

Related News

TREE NEWS share card
Long-press image above → Save to Photos / Share
Pitch us Feedback